Combined Anabolic Therapy
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age45+
SponsorMassachusetts General Hospital
About this trial
In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
Eligibility criteria
Qualifiers
women aged 45+
postmenopausal
osteoporotic with high risk of fracture
Disqualifiers
no significant previous use of bone health modifying treatments
known congenital or acquired bone disease other than osteoporosis
significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease
abnormal calcium or parathyroid hormone level
Trial design
Treatments tested in this trial
- Romosozumab
- Teriparatide
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Massachusetts General Hospital
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborator
Source ClinicalTrials.gov